Member Info for Soupdragon78

You really need the explanation of why the company dropped from being £70m Mcap to £2m.

Ok.

The chairman resigned after selling shares after not having informed the market that the Chinese partner for NXP001 had gone awol and there was no way of getting any payments from them.

Then another director resigned after selling shares at a high point just after a rumour was leaked about a potential deal with Kissei.

This leak then killed off any potential deal and burned bridges with that party.

Then Dan resigned.

Then Anne Brindley became CEO and closed down the lab and got rid of Jo Holland and Alex the lab worker, this eliminated any potential revenue stream.

Then Anne Brindley resigned as CEO less than 6 months into the job.

Alistair Riddell then stepped in as CEO and signed a disastrous funding deal with Lanstead which incentivised them to short sell the company.

Then Riddell left after no further development of the products.

Then Dan rejoined to try and salvage the company but has had to do numerous fundraising rounds as the company has no income stream available.

Does that give you enough reasons as to the sp performance?

If that’s a mystery to you then you shouldn’t really be in the share trading markets.

FFX, that’s all very good but why do you refuse to actually ask the company or Dan when you have the chance?

You know nobody here can answer your questions so it pointless continually asking them here.

‘Revelations’ lol!!!

Lol. Dinner parties! Calm down Penelope Keith.

Of course you know where this is listed, so no reason to post about AIM here then.

Dragons are never extinct as they never existed in the first place. That may just happen to be the difference, some deal with reality others wish to deal in their own fantasy world.

Keep it Pure.

Makes me glad NFX isn’t an AIM market stock,

IMHO If you don’t know what market a stock is listed on then you shouldn’t be allowed to trade it.

Laura2022 now on filter for spamming.

Lol. AIM klaxon!

Hats off to the company broker, they do an amazing job at creating a market for the placing shares.

Trombone, what would you have done differently if you were part time in charge of a company with no money, no revenue stream, no staff and no labs.

So you've sold then?

So you didn't buy the report then, but decided to post that NFX wasn't mentioned in it.

Of course you'll be aware that NFX are identified in table 2 of this independent report into the potential for inhaled IPF treatment.

https://www.tandfonline.com/doi/full/10.1080/17425247.2024.2348659#d1e109

Did you buy the report FFX? Are NFX not in the 140 listed products?

"DelveInsight’s report covers around 140+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates"

Whilst we are passing time waiting for the next news I thought I'd have a look into the enigmatic Dr Phil Molyneaux who was quoted in the last RNS regarding the EU ODD awarding.

"Phil Molyneaux, MD, Professor of Pulmonary Medicine at the Royal Brompton Hospital, London, commented: "Patients with IPF currently lack treatment options that significantly alter the course of their disease. They also often face tolerability issues with existing therapies. Inhaled therapies like NXP002 offer the potential for improved efficacy by delivering the drug directly to the lungs, while avoiding the side effects associated with oral treatments. This approach could represent a meaningful step forward in addressing the urgent need for better treatment options for patients with IPF."

Just interested as to what his background is as to any relevance of him being included for comments.

It turns out that in his role at Royal Brompton he was the clinical trial coordinator for the Phase 2a clinical trials of RedX / AstraZeneca's IPF drug RXC007, so at least he has a good IPF background.

https://www.orpha.net/en/research-trials/clinical-trial-network/626732?name=&mode=name&country=&recruiting=0&terminated=0

Well theres defo people out there with money.

Merck are buying London based lung specialist Verona Pharma for $10bn (£7.5bn).

https://www.thisismoney.co.uk/money/markets/article-14891013/US-pharma-giant-Merck-snaps-London-lung-specialist-Verona-Pharma-7-5bn.html

Hello goup, was there something you wanted?

Thanks Jiving, I just don't feel the need to spend every waking moment on here thats all.

No confirmation, but the PR company would never say 'We will now submit'

Tim has always used the terms 'the company will...'